Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
AssigneeUniversity of Central Florida Research Foundation, Inc.
InventorsGriffith Parks, Alicja Copik
Life of this patent
Estimating the term…
Abstract
Disclosed are engineered oncolytic viruses, related fusion proteins and polynucleotides encoding them, and methods for treating cancer using the engineered viruses. In one aspect, disclosed herein are engineered oncolytic viruses, wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
Claims47
An engineered oncolytic virus wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating cancer, comprising administering to a subject an engineered oncolytic virus wherein the oncolytic virus expresses one or more exogenous membrane bound immune cell targeting ligands comprising an uncleaved signal anchor.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A fusion protein comprising an uncleaved signal anchor domain comprising:
- a cytoplasmic tail region, a transmembrane region and an extracellular stalk region;
- and an immune cell targeting ligand comprising an N-terminus fused to a C-terminus of the extracellular stalk region.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.